Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer Prev Res (Phila). 2013 Mar 26;6(5):428–436. doi: 10.1158/1940-6207.CAPR-12-0431

Figure 3.

Figure 3

A, PGE-M levels were significantly different across study groups (P<0.001). Specifically, patients with lung metastasis (LM) had significantly higher urinary PGE-M levels [median (range)] (ng/mg creatinine) compared to patients with no known lung metastasis (NKLM) and the controls [6.7(0.7, 43.4) vs. 4.6 (0.7, 26.8) vs. 4.2 (0.9, 62.6), P=0.003 and P<0.001, respectively]. Urinary PGE-M levels were not significantly different between NKLM patients and the controls (P=0.34). B, PGE-M levels were significantly associated with increasing BMI (Spearman’s ρ=0.24, P<0.001). In each study group, urinary PGE-M levels [median (range)] (ng/mg creatinine) were higher in overweight/obese subjects compared to normal weight subjects [Controls: 4.6 (1.0, 62.6) vs. 3.9 (0.9, 26.8), P=0.006; Patients with NKLM: 5.5 (0.7, 26.7) vs. 4.0 (1.3, 26.8), P=0.08; Patients with LM: 7.2 (0.7, 43.4) vs. 4.9 (0.8, 22.7), P=0.03].